Beta-Thalassemia is an inherited hematologic disorder caused by various mutations of the beta-globin gene, thus resulting in a significant decrease in adult hemoglobin (HbA) production. An increase in fetal hemoglobin (HbF) levels by drug molecules is considered of great potential in Î²-thalassemia treatment and is expected to counterbalance the impaired production of HbA. In this work, based on a set of 129 experimentally tested biological inhibitors, we developed and validated a computational model for the prediction of K562 functional inhibition, possibly associated with HbF induction. To facilitate future advancements in the field, we incorporated our model into Enalos Cloud Platform, which enabled online access to our computational scheme (http://enalos.insilicotox.com/K562) through a user-friendly interface. This web service is offered to the wider community to promote insilico drug discovery through fast and reliable predictions.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||Consensus Predictive Model for Human K562 Cell Growth Inhibition through Enalos Cloud Platform|
GAMBARI, Roberto (Penultimo)
|Data di pubblicazione:||2018|
|Appare nelle tipologie:||03.1 Articolo su rivista|